 |
Prospector
Profile
07.1253
|
| |
| Optimer Pharmaceuticals, Inc. |
NAICS |
541710 |
| 10110 Sorrento Valley Road, Suite C
San Diego, CA 92121 |
Description |
Biotechnology |
| (858) 909-0736 |
Employees |
39 |
| http://www.optimerpharma.com/ |
Revenue |
(mil) |
0.9330 |
| |
Income |
(mil) |
-11.9010 |
| |
Assets |
(mil) |
24.1130 |
| |
Liability |
(mil) |
70.8150 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Optimer Pharmaceuticals, Inc. reported a net loss of $8,128,057 for the second quarter ended June 30, 2007, compared to a net loss of $3,804,782 during the second quarter of 2006. For the first of half of 2007, the Company booked a net loss of $32,632,270, much higher than the $5,891,693 net loss reported during the first half of last year. As a result of its recurring losses, the Company has an accumulated deficit of $84,190,651 in its June 30, 2007 balance sheet.
|
| |
|
Intellectual Property:
The Company has established and continues to build proprietary positions for its pipeline product candidates and technology in the United States and abroad. The Company has built a portfolio of more than 81 patents and patent applications around key products and technologies. This portfolio included 14 issued U.S. patents and 14 pending U.S. patent applications. Foreign counterparts included 11 issued patents and 47 pending patent applications. For its lead product candidate Difimicin, the Company has 2 pending PCT applications and 4 U.S. pending patent applications, and 13 pending foreign counterparts. For the product candidate Prulifloxacin, the Company has licensed 1 issued U.S. patent and 1 pending U.S. patent application from Nippon Shinyaku. The U.S. patent covers the compound Prulifloxacin. [SEC Filing 10-K 03-30-07]
|
| |
|
Description:
The Company focuses on discovering, developing, and commercializing anti-infective products primarily to treat gastrointestinal infections and related diseases.
|
| |
|
Officers:
Michael N. Chang, Ph.D. (Pres., CEO & Dir.); Tessie M. Che, Ph.D. (SVP); Sherwood L. Gorbach, M.D. (SVP & Chief Medical Officer); Kevin P. Poulos (VP); John D. Prunty (VP, Sec. & CFO); Youe-Kong Shue, Ph.D. (VP); Mark Auerbach (Dir.); Joseph Y. Chang, Ph.D. (Dir.); Joseph J. Chow (Dir.); Howard S. Lee, Ph.D. (Dir.); Martin C. Muenchbach, Ph.D. (Dir.); Alain B. Schreiber, M.D. (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol OPTR; NasdaqGM;
23,139,127 common shares outstanding as of August 1, 2007.
|
| |
| |
| |
| return to main page |
|
|
